Tagged with

Biotech The chairman of BioSingapore, Dr. Siew Hwa Ong, discusses the opportunities and challenges facing biotech SMEs in Singapore, government efforts to enhance the business environment for these SMEs, and facilitating more collaboration between companies as the most prominent pathway for future development. Could you please introduce yourself to our international…

Novartis Novartis Czech Republic’s Heidrun Irschik explains the potentially game-changing ramifications of Big Data on the Czech pharmaceutical and healthcare industries.   The opportunities offered by big data are present and we need to tap into this immense potential Heidrun Irschik, Novartis Big data: a technological phenomenon with potential commensurate to…

Pharma Teodoro Padilla, Executive Director at the Pharmaceutical and Healthcare Association of the Philippines, and Reiner Gloor, Advisor and Honorary Member, discuss the current objectives and goals of the association, how they are adapting to recent changes in the country’s healthcare landscape, and the impact of the rise of generics. To begin, could…

Pharma The below chart shows the sources of funding for R&D investment in Italy, with only 7% of total investment originating from pharmaceutical and health-oriented biotech. Click here to read more articles and interviews from Italy, and to download the latest free pharma report on the country.

Italy Italy’s traditional family-owned pharmaceutical companies are one of its greatest strengths; but these companies must be amenable to outside influence in order to grow sustainably. [There is] a lot of liquidity in the market, including amongst the family businesses … and there are now a lot of companies looking for…

Pharma The Singapore Association of Pharmaceutical Industries’ (SAPI) recently appointed president, Ti Hwei How highlights several unique attributes that distinguish Singapore’s renowned healthcare system from others around the world, while delineating three potential avenues for expanding patient access to innovative medicines. To begin, Ti Hwei, how would you characterize the specificities…

Pharma The executive director of A*STAR’s Biomedical Research Council, Dr. Benjamin Seet highlights several remarkable milestones that the organization has been able to achieve since its inception, while underscoring how cultivating deep levels of expertise will carry Singapore’s biomedical sciences sector into its next phase of development. In a few words,…

Health The chart below illustrates the potential for a shift in healthcare provision towards home care in France; a country with a rapidly increasing over 60 population, an expensive nursing home system, and a culture of living at home into old age. Click here to download the latest free pharma report on…

Pharma France provides a unique environment for dermo-cosmetics companies such as Pierre Fabre, Uriage, and Galderma to thrive in terms of the industry’s historical legacy in the country, abundant natural resources, and a tradition of openness and understanding of dermatology. [France is] a unique environment for the growth of dermo-cosmetic brands. French dermatologists have a…

Healthcare In light of the recently released OECD Reviews of Health Systems: Mexico 2016, Roberto Martinez, general director of the OECD Mexico Center for Latin America, reveals the OECD’s key findings and strategic priorities for fostering inclusive growth and better health outcomes in Mexico, while the Center keeps on strengthening its…

Pharma The expansion of universal healthcare coverage and significant growth in the use and acceptance of generics across the Philippines pose a significant challenge to the innovative medicines industry but also offers a wealth of opportunities for both international and domestic players. The Philippines now utilizes low-cost generics more than any…

Pharma The following chart shows the number of clinical trials in Italy per year. Peaking in 2008 and slumping slightly shortly after, the numbers have returned to robust levels with 550+ trials in total in 2013 and 250+ important Phase I and II trials. Click here to read more articles and…